"公司始终'以患者为中心'，通过研发创新与业务发展，为患者提供更优质的医疗解决方案。"天士力董 事长周辉日前在接受中国证券报记者专访时表示，自今年3月成为华润三九旗下成员企业以来，公司已 通过分阶段融合方案加速与华润体系协同，在明确"创新驱动"核心定位的同时，围绕三大治疗领域深化 研发布局，既发力中药创新与前沿生物药技术以补强管线，也通过多元化合作与布局以优化产品业务结 构。未来，公司还将聚焦医疗市场提升专业能力，确保产品与服务精准匹配临床需求，更将以数字化转 型夯实效率根基，精准投资完善业务生态，多维度发力以构建综合竞争力，最终致力于成为创新引领的 中国医药市场领先企业。 天士力创新中药关键技术国家实验室 公司供图 分工协作加速融合 天士力主营业务聚焦药品的研发、生产和销售，上市产品贯穿心血管与代谢、神经/精神、消化三大疾 病领域，涉及预防、治疗及康复各个环节，覆盖现代中药、生物药、化学药产品组合。其中，复方丹参 滴丸、养血清脑丸（颗粒）、替莫唑胺胶囊、普佑克等为公司主打产品，在各自治疗领域具有较强市场 竞争力。 "公司的研发方向与战略高度一致，在三大治疗领域正进一步细化重点，聚焦特定疾病领域双引擎推 进， ...

Core Viewpoint - The company aims to provide high-quality medical solutions centered around patients through innovation and business development, focusing on "innovation-driven" core positioning and deepening research and development in three major therapeutic areas [1][3]. Group 1: Business Integration and Strategy - The company has a primary focus on the research, production, and sales of pharmaceuticals, covering cardiovascular and metabolic diseases, neurological/psychiatric disorders, and digestive diseases with a diverse product portfolio [2]. - Following the acquisition by China Resources Sanjiu, the company has implemented a phased integration plan, completing the first phase successfully by the end of June, which includes cultural, business, and management integration [2][3]. - The company is positioned as a key player in the "one body, two wings" strategy of China Resources Sanjiu, emphasizing its role in innovation within the traditional Chinese medicine sector [3]. Group 2: Product Development and Pipeline - The company has 83 projects in its pipeline, with 31 being innovative drugs, and 21 in clinical phases II and III, focusing on traditional Chinese medicine [5][6]. - Specific diseases are prioritized in each core therapeutic area, with a focus on heart failure and metabolic diseases as high-risk factors for cardiovascular diseases [6]. - The company is advancing its product pipeline with several clinical trials, including traditional Chinese medicine and cutting-edge biopharmaceuticals [5][6]. Group 3: Performance and Market Strategy - The company reported a revenue of 4.288 billion yuan and a net profit of 775 million yuan in the first half of the year, reflecting a year-on-year growth of 16.97% [8]. - The company is preparing for multiple product launches in the coming years, with expectations for new drug approvals each year [8]. - The company is enhancing its international presence, having registered products in 47 countries, and is focusing on emerging markets for commercial cooperation [8]. Group 4: Digital Transformation and Innovation - The company has implemented digital management systems for quality control and production efficiency, significantly improving operational metrics [9]. - The company is actively seeking collaboration opportunities that align with its strategic direction, particularly in innovative drug development [9].